colipase like 1Genealiases: C6orf127 · ESP32 · dJ510O8.6
Q-omics provides the consensus-scored CLPSL1 profile across patient tissues and cancer cell-line models. CLPSL1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLPSL1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CLPSL1 RNA expression shows 9,504 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where CLPSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLPSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLPSL1 survival associations across molecular data types. CLPSL1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLPSL1 RNA expression–survival associations across cancer types. High CLPSL1 expression shows unfavorable associations in KIRC, COAD, READ, SCLC and LIHC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLPSL1 RNA expression.
This table summarizes CLPSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CLPSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLPSL1 shows lower tumor expression in KIRC and higher tumor expression in LUAD, UCEC, BRCA, BLCA and LUSC. The LUAD box plot shows higher CLPSL1 RNA expression in tumor versus normal tissue (log2 FC = +0.927, t-test p < 0.001).
This table shows molecular features associated with CLPSL1 in patient tissues and cancer cell lines. In patient samples, CLPSL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLPSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
